What's breaking now, across thousands of outlets.
AbbVie said its T cell engager etentamig cut the risk of disease progression or death by 60% compared with standard therapies in a Phase 3 multiple myeloma trial. The Chicago-area company is now planning to ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.
This is one outlet's version. Read the fullest account.
An invasive mosquito species known to transmit diseases such as the dengue and Zika viruses has been found to be breeding in the UK for the first time.
Ultragenyx drug fails pivotal Phase 3, FDA's success at regulating unproven stem cells, and other biotech news
The FSSAI has ordered the CG Foods India factory to stop producing certain Wai Wai products due to safety violations. Inspections revealed the reuse of broken noodles and unlicensed production…
The failure of what was once considered a potential blockbuster therapy represents a major setback in a tough-to-treat disease and is forcing Ultragenyx to closely examine its expenses.
What if we had this wrong? Don't miss a story, subscribe here.
Historically, cerebral palsy (CP) was linked largely to events at birth, including prematurity or temporary loss of oxygen to the brain, but research over the past decade has suggested that genetic…
